Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint
Go back to Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint| (NASDAQ: XENE) | Delayed: 54.79 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.79 | 52 Week High | $9.75 | |||
| Open | $54.79 | 52 Week Low | $5.65 | |||
| Day High | $54.79 | P/E | N/A | |||
| Day Low | $54.79 | EPS | $0.00 | |||
| Volume | 1 | |||||
